Atsuo Tahara

2.9k total citations
82 papers, 2.4k citations indexed

About

Atsuo Tahara is a scholar working on Social Psychology, Endocrinology, Diabetes and Metabolism and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Atsuo Tahara has authored 82 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Social Psychology, 32 papers in Endocrinology, Diabetes and Metabolism and 31 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Atsuo Tahara's work include Neuroendocrine regulation and behavior (34 papers), Electrolyte and hormonal disorders (30 papers) and Diabetes Treatment and Management (28 papers). Atsuo Tahara is often cited by papers focused on Neuroendocrine regulation and behavior (34 papers), Electrolyte and hormonal disorders (30 papers) and Diabetes Treatment and Management (28 papers). Atsuo Tahara collaborates with scholars based in Japan, Norway and Netherlands. Atsuo Tahara's co-authors include Toshiyuki Takasu, Masayuki Shibasaki, Yuichi Tomura, Junko Tsukada, Masanori Yokono, Eiji Kurosaki, Takeyuki Yatsu, Masakazu Imamura, Wataru Uchida and Koh‐ichi Wada and has published in prestigious journals such as Journal of the American Chemical Society, Biochemical and Biophysical Research Communications and Journal of Medicinal Chemistry.

In The Last Decade

Atsuo Tahara

81 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Atsuo Tahara Japan	25	997	958	597	576	560	82	2.4k
Giampiero Bricca France	27	287 0.3×	1.0k 1.1×	270 0.5×	222 0.4×	87 0.2×	105	2.5k
Kerstin Richter Germany	20	612 0.6×	1.4k 1.4×	355 0.6×	443 0.8×	37 0.1×	32	2.4k
T Unger Germany	25	590 0.6×	948 1.0×	191 0.3×	151 0.3×	222 0.4×	66	2.6k
Tetsuo Nakata Japan	24	314 0.3×	369 0.4×	305 0.5×	115 0.2×	81 0.1×	93	1.7k
Motoaki Saito Japan	28	329 0.3×	610 0.6×	448 0.8×	238 0.4×	35 0.1×	192	2.6k
Jean‐Louis Junien France	34	414 0.4×	1.5k 1.5×	330 0.6×	192 0.3×	137 0.2×	76	3.0k
Hiroki Yoshimi Japan	28	345 0.3×	946 1.0×	229 0.4×	221 0.4×	82 0.1×	71	2.7k
Zhice Xu China	25	225 0.2×	530 0.6×	112 0.2×	216 0.4×	221 0.4×	112	2.0k
Susumu Miyabo Japan	23	384 0.4×	363 0.4×	382 0.6×	243 0.4×	55 0.1×	99	1.6k
Chunyu Zeng China	29	532 0.5×	1.6k 1.7×	209 0.4×	184 0.3×	42 0.1×	99	2.6k

Countries citing papers authored by Atsuo Tahara

Since Specialization

Citations

This map shows the geographic impact of Atsuo Tahara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Atsuo Tahara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Atsuo Tahara more than expected).

Fields of papers citing papers by Atsuo Tahara

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Atsuo Tahara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Atsuo Tahara. The network helps show where Atsuo Tahara may publish in the future.

Co-authorship network of co-authors of Atsuo Tahara

This figure shows the co-authorship network connecting the top 25 collaborators of Atsuo Tahara. A scholar is included among the top collaborators of Atsuo Tahara based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Atsuo Tahara. Atsuo Tahara is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tahara, Atsuo. (2021). Effects of SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone on fluid retention in type 2 diabetic mice with NASH. European Journal of Pharmacology. 901. 174076–174076. 8 indexed citations

Kondo, Mitsuhiro, et al.. (2020). Therapeutic effects of interleukin-1 receptor-associated kinase 4 inhibitor AS2444697 on diabetic nephropathy in type 2 diabetic mice. Naunyn-Schmiedeberg s Archives of Pharmacology. 393(7). 1197–1209. 9 indexed citations

Tahara, Atsuo, et al.. (2018). Effects of the SGLT2 inhibitor ipragliflozin on food intake, appetite-regulating hormones, and arteriovenous differences in postprandial glucose levels in type 2 diabetic rats. Biomedicine & Pharmacotherapy. 105. 1033–1041. 10 indexed citations

Tahara, Atsuo & Toshiyuki Takasu. (2018). Antidiabetic effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed diets containing different carbohydrate contents. Life Sciences. 197. 80–90.

Tahara, Atsuo, Toshiyuki Takasu, Masanori Yokono, Masakazu Imamura, & Eiji Kurosaki. (2017). Characterization and comparison of SGLT2 inhibitors: Part 3. Effects on diabetic complications in type 2 diabetic mice. European Journal of Pharmacology. 809. 163–171. 44 indexed citations

Tahara, Atsuo, Toshiyuki Takasu, Masanori Yokono, Masakazu Imamura, & Eiji Kurosaki. (2016). Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects. Journal of Pharmacological Sciences. 130(3). 159–169. 112 indexed citations

Yokono, Masanori, Atsuo Tahara, Eiji Kurosaki, et al.. (2013). Pharmacological Characterization of YM543, a Newly Synthesized, Orally Active SGLT2 Selective Inhibitor. Endocrine Research. 38(3). 168–183. 4 indexed citations

Tahara, Atsuo, Junko Tsukada, Yuichi Tomura, Takeyuki Yatsu, & Masayuki Shibasaki. (2012). Effects of High Glucose on AVP-Induced Hyperplasia, Hypertrophy, and Type IV Collagen Synthesis in Cultured Rat Mesangial Cells. Endocrine Research. 37(4). 216–227. 12 indexed citations

Tahara, Atsuo, et al.. (2009). Antidiabetic effects of dipeptidyl peptidase–IV inhibitors and sulfonylureas in streptozotocin-nicotinamide–induced mildly diabetic mice. Metabolism. 58(3). 379–386. 14 indexed citations

10.

Tahara, Atsuo, Ryosuke Nakano, Itsuro Nagase, et al.. (2008). Pharmacological profile of ASP8497, a novel, selective, and competitive dipeptidyl peptidase-IV inhibitor, in vitro and in vivo. Naunyn-Schmiedeberg s Archives of Pharmacology. 377(3). 209–217. 10 indexed citations

11.

Tahara, Atsuo, et al.. (2008). Hypoglycaemic Effects of Antidiabetic Drugs in Streptozotocin‐Nicotinamide‐Induced Mildly Diabetic and Streptozotocin‐Induced Severely Diabetic Rats. Basic & Clinical Pharmacology & Toxicology. 103(6). 560–568. 50 indexed citations

12.

Shimada, Yoshiaki, Nobuaki Taniguchi, Akira Matsuhisa, et al.. (2005). Preparation of Highly Potent and Selective Non-Peptide Antagonists of the Arginine Vasopressin V1A Receptor by Introduction of a 2-Ethyl-1H-1-imidazolyl Group. Chemical and Pharmaceutical Bulletin. 53(7). 764–769. 9 indexed citations

13.

Tahara, Atsuo, Junko Tsukada, Yuichi Tomura, et al.. (2003). Alterations of Renal Vasopressin V<sub>1A</sub> and V<sub>2</sub> Receptors in Spontaneously Hypertensive Rats. Pharmacology. 67(2). 106–112. 11 indexed citations

14.

Tsukada, Junko, Atsuo Tahara, Yuichi Tomura, et al.. (2002). Pharmacological characterization of YM471, a novel potent vasopressin V1A and V2 receptor antagonist. European Journal of Pharmacology. 446(1-3). 129–138. 13 indexed citations

15.

Tsukada, Junko, Atsuo Tahara, Yuichi Tomura, et al.. (2001). Effects of YM471, a nonpeptide AVP V_1A and V₂ receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells. British Journal of Pharmacology. 133(5). 746–754. 10 indexed citations

16.

Tahara, Atsuo, Masayuki Saito, Toru Sugimoto, et al.. (1999). AVP-induced mitogenic responses of Chinese hamster ovary cells expressing human V 1A or V 1B receptors. Pflügers Archiv - European Journal of Physiology. 437(2). 219–226. 9 indexed citations

17.

Yatsu, Takeyuki, Yuichi Tomura, Atsuo Tahara, et al.. (1999). Pharmacology of conivaptan hydrochloride (YM087), a novel vasopressin V1A/V2 receptor antagonist. Folia Pharmacologica Japonica. 114(supplement). 113–117. 3 indexed citations

18.

Tahara, Atsuo, Yuichi Tomura, Koh‐ichi Wada, et al.. (1998). Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte. Cardiovascular Research. 38(1). 198–205. 57 indexed citations

19.

Tahara, Atsuo, Masayuki Saito, Toru Sugimoto, et al.. (1997). Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist. Naunyn-Schmiedeberg s Archives of Pharmacology. 357(1). 63–69. 44 indexed citations

20.

Yatsu, Takeyuki, Yuichi Tomura, Atsuo Tahara, et al.. (1997). Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V1A and V2 receptor antagonist, in dogs. European Journal of Pharmacology. 321(2). 225–230. 59 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact